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abdominal surgery in Smolensk Regional Hospital (SRH)
and to assess the impact of educational (lectures, infor-
mation bulletin) and administrative (practical recommen-
dations) activity in SRH on ABP practice. METHODS:
Analysis was based on patient data gathered retrospec-
tively between 01/01/93–01/07/93 and 01/01/98–01/07/
98. Three hundred and twenty seven patients who under-
went open cholecystectomy (OCE), appendectomy (AE)
and hernia repair (HR) were included in analysis. ABP
frequency and quality (selection of antimicrobials, dosage
regimens, route of administration, post-operative dura-
tion) were assessed. For economic evaluation ABP Thresh-
old Cost/Wound Infection Treatment Cost (ABP-TC/
WITC) ratio was estimated. ABP-TC was calculated by
multiplication Numbers Needed to Treat and ABP cost.
RESULTS: In 1993 none of the patients received ABP, in
1998 the following ABP frequency was registered: OCE-
78% (77/99), HR-46% (18/39), AE-0%. In case of OCE,
I–II and III generation cephalosporins were administrated
in 57% and 47% cases, respectively. AB dosages, routes
of administrations were appropriate in all cases. TC-
ABP/WITC ratio for OCE was 520/5355  1/10.3 (RUB,
1999). In 1993 antibacterial administration without evi-
dence of postoperative infection was registered for OCE
in 82%, AE-68%, HR-33% cases; in 1998 for OCE in
31%, AE-68%, HR-34% cases. CONCLUSION: (1) ABP
in OCE is cost-effective compared to no-ABP strategy
and leads to 10 times reduction of hospital costs; (2) Edu-
cational and administrative activities have a positive im-
pact on ABP practice; (3) Monitoring of ABP practice
and feedback to surgeons should be implemented in hos-
pitals for the optimization of ABP.
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OBJECTIVE: to evaluate the structure and the admission
process for acute pyelonephritis (APN) and to qualify the
different alternatives. To calculate costs associated to any
therapeutic, antibiotic or not, and diagnostic, laboratory
or instrumental pathway and to notice their behaviours.
To estimate the amount of this share of hospital costs on the
global and to compare them to reimbursement. METHODS:
A retrospective analysis was made of all admissions with
a diagnosis of APN in the Nephrology Department of
Ravenna Local Health Unit between 1/1/1985 and 31/12/
1998 as well as an assessment of therapeutic costs and di-
agnostic charges (defined clinical costs) and reimburse-
ments in accordance with the DRG. Data were collected
thanks to a specific software purposely developed. An
economic analysis was conducted relating costs to length
of stay and to risk factors. RESULTS: The number of pa-
tients admitted was determined (69 females and 8 males,
aged 35.4  16.8). Average duration of hospitalization:
11.2  3.2 days. Total clinical costs: ITL. 81,389,282,
69.3% due to tests and 30,7 to drugs (mean cost per patient:
ITL. 1,190,015 for DRG 320, ITL. 1,049,115 for DRG 321
and ITL. 832,540 for DRG 322, respectively: 22.9%,
31.7%, and 24.6% of the reimbursement). Clinical costs
peaked in first days, caused by diagnostic ones, then
tailed off gradually. The 62.7% of tests was performed
within the third day. The mean cost of this period next to
admission was the 37.9% of the total mean cost per pa-
tient. DISCUSSION: the analytical knowledge of diag-
nostic and therapeutics pathways premises to find out the
clinical algorithms and their costs and to analyze the rela-
tionship between resources and results. The clinical costs
for the APN patient in hospital account for a consider-
able share of the DRG reimbursement which may there-
fore be “overbalanced” by the hotel costs (not clinical).
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OBJECTIVES: To investigate how price elasticity of de-
mand reflects consumers’ response to price change by
means of ATC/DDD analysis for evaluation of consump-
tion and comparative sale and price analysis, referred to
two antibiotics in oral dosage forms, ampicillin (A) and
amoxicillin (Ax). METHODS: Data were gathered from:
a) the import of wholesalers, b) the reports of local man-
ufacturers for the domestic market. RESULTS: The in-
crease of drug price under elastic demand results in de-
crease of demand (in packs), while in inelastic demand
higher price will cause increase in sales. Demand curve
may affect drug consumption presented in DDD/1000/
day as well as price per 1 g active substance. Two kinds
of ampicillin (A1 and A2) and amoxicillin (Ax1 and Ax2),
both market leaders in terms of demand, were analyzed.
In 1995, A1 and Ax1 had lower price (per pack) and dou-
ble sales than A2 and Ax2. However A1 and Ax1 had elas-
tic demand-
  2.11 for A1 and 
  2.32 for Ax1. The de-
mand for A2 and Ax2 was inelastic (
  0.29 and 
 
0.58). In ampicillines A1 increased the price, A2 decreased
the price. In 1999, they both had lower sales. Further-
more, DDD/1000/day for A1 dropped from 1.15 in 1995
to 0.56 in 1999, the price per 1 g active substance also
was reduced. In amoxicillines, both products increased
the price. Ax1, being in elastic condition in 1995, de-
creased the quantity of demand twice. Ax2, starting from
inelastic market, increased the price and in 1999 ob-
tained considerable augmentation of sales, higher DDD/
1000/day/from 1.2 to 2.58/and lower price per 1 g active
substance. CONCLUSIONS: The degree of elasticity of
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demand shows how consumers feel about a particular
product and its substitutes, thus having direct economical
impact on consumption.
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OBJECTIVE: To investigate the incremental cost-effec-
tiveness of ganciclovir relative to acyclovir in preventing
cytomegalovirus disease (CMV) after liver transplanta-
tion, using Bayesian methods. METHODS: Analysis was
based on 134 patients in a randomized clinical trial com-
paring oral acyclovir (ACV) to intravenous ganciclovir
followed by oral acyclovir (GCV). Probability of CMV,
ICU and non-ICU days and total billed charges were
modeled as interdependent binomial, poison and log-
transformed linear regressions of recipient, donor and
surgery covariates using Markov Chain Monte Carlo
(MCMC) with non-informative priors. RESULTS: The
posterior median (PM) attributable risk reduction for
CMV ranged from 16% (95% posterior range (PR): 5%–
22%) when both recipients and donors are previously ex-
posed to cytomegalovirus (R/D) to 29% (95%PR:
7%–43%) when recipients are not exposed, but donors
are (R/D). For average patients, CMV infection yields
a PM 3.5 ICU day increase (95%PR: 2.3–5.0) and a PM
1.9 non-ICU day increase (95%PR: .2–3.7). The associa-
tion of additional days with total charges is non-linear.
On average, increasing ICU-days from 4 to 5 yields a PM
increase in total billed charges of $3,692 (95%PR: $2,501–
$4,955), and increasing non-ICU days from 12 to 13
yields a PM increase of $1,311 (95%PR: $610–$2,052).
Independent of the impact on days, CMV yields a PM
$17,638 charge increase (95%PR $5,539–$31,220). The
average incremental cost-effectiveness for the study sample
is a 14.8% risk reduction and $12,048 savings. 73.1%
percent of the probability mass of the incremental cost-
effectiveness distribution lies in the “dominant quadrant”
(GCV reduces infections and total charges). For R/D
cases, GCV dominates ACV 93.5% of the time, and aver-
age incremental cost-effectiveness is a 27.1% risk reduc-
tion and $19,545 savings. CONCLUSION: The study
demonstrates cost-effectiveness of GCV relative to ACV
in prevention of CMV post transplant. The model explic-
itly associates covariates and treatment with cost-effec-
tiveness, reflecting uncertainty using a Bayesian frame-
work.
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Antibiotic misuse is a growing national concern. Sinusitis
is the leading indication for adult antibiotic outpatient
prescriptions. Physician prescribing behavior was care-
fully reviewed in treating sinusitis with approved antibi-
otic agents. METHODS: All subjects with pharmacy
claims for acute sinusitis (ICD9-CM code of 461) in the
year 1997 to 1998 from a 932,000 enrollee Midwest in-
surance company were included in the study. A logistic
regression model (N  12,765) was used to identify fac-
tors affecting the choice of antibiotic, with clarithromy-
cin prescription coded as “1” and any other antibiotic
prescription (amoxicillin, amoxicillin-clavulanate, eryth-
romycin, erythromycinsulfisox, loracarbef, cephalosporin,
azithromycin) coded as “0”. The independent variables
included in the model were age category (12–20, 21–40,
41–65, and 65 years or older), gender, success rate for
each antibiotic, incidence of second, third or fourth epi-
sode within the year, pre and intra-episode severity. RE-
SULTS: The mean age of subjects was 29.7 ( 17.8)
years. The prevalence rate of sinusitis was 12 cases per
1000, of which, 13 percent had two or more episodes of
sinusitis within a year. Patients with two episodes were
19 times more likely to get initial treatment with clarithro-
mycin than patients in first episode. The odds of treat-
ment initiation with clarithromycin were 27 percent
higher when age increased by one categorical unit. The
odds of treatment initiation with clarithromycin was 18
percent higher in women compared to men. CONCLU-
SION: The results indicated that clarithromycin is used
more often for treating sinusitis in patients who have
multiple episodes. Generalization of this analysis needs to
be confirmed using data from multiple managed care plans.
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OBJECTIVES: The clinical course of chronic bronchitis is
characterized by acute exacerbations (AECB), during which
